Montelukast added to fluticasone propionate does not alter inflammation or outcomes

Ratko Djukanović, Susan J. Wilson, Wendy C. Moore, Steven M. Koenig, Michel Laviolette, Eugene R. Bleecker, W. Bruce Davis, Dennis E. Doherty, Ronald Olivenstein, Elliott Israel, Mani S. Kavuru, Eric Kleerup, Donna S. Reilly, Steven W. Yancey, Lisa D. Edwards, John L. Stauffer, Paul M. Dorinsky, Nizar N. Jarjour

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Airway inflammation is a key pathological feature of asthma which underlies its clinical presentation. Objectives: To examine whether adding a leukotriene modifier to an inhaled corticosteroid produces further clinical and/or anti-inflammatory benefits in patients symptomatic on short-acting β2-agonists. Methods: Patients uncontrolled on short-acting β2-agonists were treated for 12 weeks with either fluticasone propionate (100 mcg BD) or fluticasone propionate (100 mcg BD) and montelukast (10 mg QD) in a randomized, double-blind, parallel group study. Bronchoscopy with endobronchial biopsy and bronchoalveolar lavage (BAL) was performed before and after treatment to compare effects on airway inflammation. Results: Of 103 subjects enrolled, 89 subjects completed treatment and 82 subjects had matched pair biopsy samples. Submucosal eosinophil counts, the primary endpoint, and asthma control improved to similar extents after both treatments (p ≤ 0.008). Both treatments significantly reduced submucosal mast cell, CD3+, CD4+, CD8+ and CD25+ cell counts. Submucosal mast cell reduction was greater in the fluticasone propionate plus montelukast group. There were no differences between treatments in BAL markers of inflammation or thickness of sub-epithelial collagen. Conclusions: Low-dose fluticasone propionate significantly improves clinical disease control and reduces airway inflammation in asthma patients uncontrolled with short-acting β2-agonists without further improvement when montelukast is added to low-dose fluticasone propionate.

Original languageEnglish (US)
Pages (from-to)1425-1435
Number of pages11
JournalRespiratory Medicine
Volume104
Issue number10
DOIs
StatePublished - Jan 1 2010

Fingerprint

montelukast
Inflammation
Asthma
Bronchoalveolar Lavage
Mast Cells
Biopsy
Therapeutics
Airway Management
Leukotrienes
Bronchoscopy
Eosinophils
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Collagen
Cell Count
Fluticasone

Keywords

  • Airway inflammation
  • Asthma
  • Bronchoscopy
  • Eosinophils
  • Fluticasone propionate
  • Montelukast

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Djukanović, R., Wilson, S. J., Moore, W. C., Koenig, S. M., Laviolette, M., Bleecker, E. R., ... Jarjour, N. N. (2010). Montelukast added to fluticasone propionate does not alter inflammation or outcomes. Respiratory Medicine, 104(10), 1425-1435. https://doi.org/10.1016/j.rmed.2010.04.004

Montelukast added to fluticasone propionate does not alter inflammation or outcomes. / Djukanović, Ratko; Wilson, Susan J.; Moore, Wendy C.; Koenig, Steven M.; Laviolette, Michel; Bleecker, Eugene R.; Davis, W. Bruce; Doherty, Dennis E.; Olivenstein, Ronald; Israel, Elliott; Kavuru, Mani S.; Kleerup, Eric; Reilly, Donna S.; Yancey, Steven W.; Edwards, Lisa D.; Stauffer, John L.; Dorinsky, Paul M.; Jarjour, Nizar N.

In: Respiratory Medicine, Vol. 104, No. 10, 01.01.2010, p. 1425-1435.

Research output: Contribution to journalArticle

Djukanović, R, Wilson, SJ, Moore, WC, Koenig, SM, Laviolette, M, Bleecker, ER, Davis, WB, Doherty, DE, Olivenstein, R, Israel, E, Kavuru, MS, Kleerup, E, Reilly, DS, Yancey, SW, Edwards, LD, Stauffer, JL, Dorinsky, PM & Jarjour, NN 2010, 'Montelukast added to fluticasone propionate does not alter inflammation or outcomes', Respiratory Medicine, vol. 104, no. 10, pp. 1425-1435. https://doi.org/10.1016/j.rmed.2010.04.004
Djukanović R, Wilson SJ, Moore WC, Koenig SM, Laviolette M, Bleecker ER et al. Montelukast added to fluticasone propionate does not alter inflammation or outcomes. Respiratory Medicine. 2010 Jan 1;104(10):1425-1435. https://doi.org/10.1016/j.rmed.2010.04.004
Djukanović, Ratko ; Wilson, Susan J. ; Moore, Wendy C. ; Koenig, Steven M. ; Laviolette, Michel ; Bleecker, Eugene R. ; Davis, W. Bruce ; Doherty, Dennis E. ; Olivenstein, Ronald ; Israel, Elliott ; Kavuru, Mani S. ; Kleerup, Eric ; Reilly, Donna S. ; Yancey, Steven W. ; Edwards, Lisa D. ; Stauffer, John L. ; Dorinsky, Paul M. ; Jarjour, Nizar N. / Montelukast added to fluticasone propionate does not alter inflammation or outcomes. In: Respiratory Medicine. 2010 ; Vol. 104, No. 10. pp. 1425-1435.
@article{cf5729b3b79b40a9a5f6a004a00fcf95,
title = "Montelukast added to fluticasone propionate does not alter inflammation or outcomes",
abstract = "Background: Airway inflammation is a key pathological feature of asthma which underlies its clinical presentation. Objectives: To examine whether adding a leukotriene modifier to an inhaled corticosteroid produces further clinical and/or anti-inflammatory benefits in patients symptomatic on short-acting β2-agonists. Methods: Patients uncontrolled on short-acting β2-agonists were treated for 12 weeks with either fluticasone propionate (100 mcg BD) or fluticasone propionate (100 mcg BD) and montelukast (10 mg QD) in a randomized, double-blind, parallel group study. Bronchoscopy with endobronchial biopsy and bronchoalveolar lavage (BAL) was performed before and after treatment to compare effects on airway inflammation. Results: Of 103 subjects enrolled, 89 subjects completed treatment and 82 subjects had matched pair biopsy samples. Submucosal eosinophil counts, the primary endpoint, and asthma control improved to similar extents after both treatments (p ≤ 0.008). Both treatments significantly reduced submucosal mast cell, CD3+, CD4+, CD8+ and CD25+ cell counts. Submucosal mast cell reduction was greater in the fluticasone propionate plus montelukast group. There were no differences between treatments in BAL markers of inflammation or thickness of sub-epithelial collagen. Conclusions: Low-dose fluticasone propionate significantly improves clinical disease control and reduces airway inflammation in asthma patients uncontrolled with short-acting β2-agonists without further improvement when montelukast is added to low-dose fluticasone propionate.",
keywords = "Airway inflammation, Asthma, Bronchoscopy, Eosinophils, Fluticasone propionate, Montelukast",
author = "Ratko Djukanović and Wilson, {Susan J.} and Moore, {Wendy C.} and Koenig, {Steven M.} and Michel Laviolette and Bleecker, {Eugene R.} and Davis, {W. Bruce} and Doherty, {Dennis E.} and Ronald Olivenstein and Elliott Israel and Kavuru, {Mani S.} and Eric Kleerup and Reilly, {Donna S.} and Yancey, {Steven W.} and Edwards, {Lisa D.} and Stauffer, {John L.} and Dorinsky, {Paul M.} and Jarjour, {Nizar N.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.rmed.2010.04.004",
language = "English (US)",
volume = "104",
pages = "1425--1435",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Montelukast added to fluticasone propionate does not alter inflammation or outcomes

AU - Djukanović, Ratko

AU - Wilson, Susan J.

AU - Moore, Wendy C.

AU - Koenig, Steven M.

AU - Laviolette, Michel

AU - Bleecker, Eugene R.

AU - Davis, W. Bruce

AU - Doherty, Dennis E.

AU - Olivenstein, Ronald

AU - Israel, Elliott

AU - Kavuru, Mani S.

AU - Kleerup, Eric

AU - Reilly, Donna S.

AU - Yancey, Steven W.

AU - Edwards, Lisa D.

AU - Stauffer, John L.

AU - Dorinsky, Paul M.

AU - Jarjour, Nizar N.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background: Airway inflammation is a key pathological feature of asthma which underlies its clinical presentation. Objectives: To examine whether adding a leukotriene modifier to an inhaled corticosteroid produces further clinical and/or anti-inflammatory benefits in patients symptomatic on short-acting β2-agonists. Methods: Patients uncontrolled on short-acting β2-agonists were treated for 12 weeks with either fluticasone propionate (100 mcg BD) or fluticasone propionate (100 mcg BD) and montelukast (10 mg QD) in a randomized, double-blind, parallel group study. Bronchoscopy with endobronchial biopsy and bronchoalveolar lavage (BAL) was performed before and after treatment to compare effects on airway inflammation. Results: Of 103 subjects enrolled, 89 subjects completed treatment and 82 subjects had matched pair biopsy samples. Submucosal eosinophil counts, the primary endpoint, and asthma control improved to similar extents after both treatments (p ≤ 0.008). Both treatments significantly reduced submucosal mast cell, CD3+, CD4+, CD8+ and CD25+ cell counts. Submucosal mast cell reduction was greater in the fluticasone propionate plus montelukast group. There were no differences between treatments in BAL markers of inflammation or thickness of sub-epithelial collagen. Conclusions: Low-dose fluticasone propionate significantly improves clinical disease control and reduces airway inflammation in asthma patients uncontrolled with short-acting β2-agonists without further improvement when montelukast is added to low-dose fluticasone propionate.

AB - Background: Airway inflammation is a key pathological feature of asthma which underlies its clinical presentation. Objectives: To examine whether adding a leukotriene modifier to an inhaled corticosteroid produces further clinical and/or anti-inflammatory benefits in patients symptomatic on short-acting β2-agonists. Methods: Patients uncontrolled on short-acting β2-agonists were treated for 12 weeks with either fluticasone propionate (100 mcg BD) or fluticasone propionate (100 mcg BD) and montelukast (10 mg QD) in a randomized, double-blind, parallel group study. Bronchoscopy with endobronchial biopsy and bronchoalveolar lavage (BAL) was performed before and after treatment to compare effects on airway inflammation. Results: Of 103 subjects enrolled, 89 subjects completed treatment and 82 subjects had matched pair biopsy samples. Submucosal eosinophil counts, the primary endpoint, and asthma control improved to similar extents after both treatments (p ≤ 0.008). Both treatments significantly reduced submucosal mast cell, CD3+, CD4+, CD8+ and CD25+ cell counts. Submucosal mast cell reduction was greater in the fluticasone propionate plus montelukast group. There were no differences between treatments in BAL markers of inflammation or thickness of sub-epithelial collagen. Conclusions: Low-dose fluticasone propionate significantly improves clinical disease control and reduces airway inflammation in asthma patients uncontrolled with short-acting β2-agonists without further improvement when montelukast is added to low-dose fluticasone propionate.

KW - Airway inflammation

KW - Asthma

KW - Bronchoscopy

KW - Eosinophils

KW - Fluticasone propionate

KW - Montelukast

UR - http://www.scopus.com/inward/record.url?scp=77956342708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956342708&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2010.04.004

DO - 10.1016/j.rmed.2010.04.004

M3 - Article

C2 - 20709517

AN - SCOPUS:77956342708

VL - 104

SP - 1425

EP - 1435

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 10

ER -